Evaluation of patients after extraperitoneal lymph node dissection for cervical cancer

被引:56
作者
Denschlag, D
Gabriel, B
Mueller-Lantzsch, C
Tempfer, C
Henne, K
Gitsch, G
Hasenburg, A
机构
[1] Univ Freiburg, Sch Med, Dept Obstet & Gynecol, D-79106 Freiburg, Germany
[2] Univ Freiburg, Sch Med, Dept Radiotherapy, D-79106 Freiburg, Germany
关键词
cervical cancer; EPLND; lymph nodes;
D O I
10.1016/j.ygyno.2004.08.053
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The presence of nodal metastases is an important prognostic factor in patients with cervical cancer. To adjust our therapy to the anatomic extent of the disease, we performed a surgical staging with extraperitoneal lymph node dissection (EPLND). The goal of our Study was to evaluate the clinical outcome and side effects of the combined treatment approach of EPLND and either radical hysterectomy in case of early stage cervical cancer (FIGO Ia/b and IIa) and negative nodes, or pelvic radiotherapy/extended field radiotherapy with concomitant chemotherapy in case of positive nodes or advanced stage cervical cancer (FIGO IIb, III, and IVa). Patients and methods. Fifty-nine patients with primarily diagnosed invasive cervical cancer underwent EPLND. The value of this procedure as a diagnostic tool for evaluating the extent of disease was determined. Additionally, treatment-related complications and clinical outcomes were monitored. Results. A total of 983 lymph nodes were removed during EPLND (mean 16.7). According to the results of EPLND, radical hysterectomy was abandoned due to histopathologically confirmed lymph node involvement by frozen section in I I out of 36 patients with early stage cervical cancer (31%). The most common adverse effects directly related to surgery in general (EPLND or combined EPLND and radical hysterectomy) were lymph cysts in seven patients (12%). Only in the group of patients who received EPLND followed by radical hysterectomy, 2 out of 25 patients (8%) developed a severe ileus postoperatively (WHO Grade 3 toxicity). The treatment approach of combined EPLND followed by radio- and chemotherapy was without major complications (WHO Grade 3 or 4 toxicity). After a mean follow up of 28 months (range 6-60), 44 out of 58 patients (one patient lost to follow Lip) are without evidence of disease (76%), 2 patients have progressive disease (3%), and 12 patients died of their disease (21%). Using Kaplan-Meier analysis, the estimated 5-year overall survival rate for all patients is 64% (SD +/- 9%). Performing the Cox proportional regression analysis, in contrast to clinical FIGO staging (P = 0.24; ns), lymph node involvement was the only significant independent predictor for overall survival (P = 0.04). Conclusion. Our data support the approach of pretherapeutic Surgical staging by performing EPLND as a diagnostic tool with a low complication rate. This allows an individualized treatment for cervical cancer patients. (c) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:658 / 664
页数:7
相关论文
共 45 条
[1]  
ACOG, 2002, INT J GYNECOL OBSTET, V76, P95
[2]   IDENTIFICATION OF PROGNOSTIC FACTORS AND RISK GROUPS IN PATIENTS FOUND TO HAVE NODAL METASTASIS AT THE TIME OF RADICAL HYSTERECTOMY FOR EARLY-STAGE SQUAMOUS CARCINOMA OF THE CERVIX [J].
ALVAREZ, RD ;
SOONG, SJ ;
KINNEY, WK ;
REID, GC ;
SCHRAY, MF ;
PODRATZ, KC ;
MORLEY, GW ;
SHINGLETON, HM .
GYNECOLOGIC ONCOLOGY, 1989, 35 (02) :130-135
[3]  
AYHAN A, 1991, EUR J SURG ONCOL, V17, P492
[4]   Prognostic factors in adenocarcinoma of the uterine cervix [J].
Baalbergen, A ;
Ewing-Graham, PC ;
Hop, WCJ ;
Struijk, P ;
Helmerhorst, TJM .
GYNECOLOGIC ONCOLOGY, 2004, 92 (01) :262-267
[5]   Contribution of whole-body 18FDG PET imaging in the management of cervical cancer [J].
Belhocine, T ;
Thille, A ;
Fridman, V ;
Albert, A ;
Seidel, L ;
Nickers, P ;
Kridelka, F ;
Rigo, P .
GYNECOLOGIC ONCOLOGY, 2002, 87 (01) :90-97
[6]  
BERMAN ML, 1977, OBSTET GYNECOL, V50, P658
[7]   Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review [J].
Bipat, S ;
Glas, AS ;
van der Velden, J ;
Zwinderman, AH ;
Bossuyt, PMM ;
Stoker, J .
GYNECOLOGIC ONCOLOGY, 2003, 91 (01) :59-66
[8]  
Cosin JA, 1998, CANCER, V82, P2241, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2241::AID-CNCR20>3.0.CO
[9]  
2-T
[10]  
DOWNEY GO, 1989, AM J OBSTET GYN S1, V160, pT61